NEW YORK, July 21, 2017 -- Pomerantz LLP announces that a class action lawsuit has been filed against Eco Science Solutions, Inc. (“Eco Science” or the “Company”) (OTCQB:ESSI) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-03760, is on behalf of a class consisting of investors who purchased or otherwise acquired Eco Science securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Eco Science securities between May 1, 2017 and May 19, 2017, both dates inclusive, you have until July 24, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
[Click here to join this class action]
Eco Science Solutions, Inc. is a technology-focused company that provides solutions for the health and wellness industry. The Company provides enterprise software solutions and services including consumer apps, localized communication platforms between consumers and businesses, educational content, e-commerce platforms, and social networking services.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s plan for strategic acquisitions lacked veracity; and (ii) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.
On May 19, 2017, the Securities and Exchange Commission issued an order of suspension of trading, halting trading of the Company’s securities. To date, trading the Company’s securities remains halted, rending the Company’s securities illiquid and virtually worthless, thereby damaging investors.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]


Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
FDA Approves Mitapivat for Anemia in Thalassemia Patients
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 



